WARNER-LAMBERT FAJARDO, P.R. PLANT TO BE TAKEN OFF FDA INTEGRITY POLICY SOON, FIRM SAYS; FAILURE TO REPORT DILANTIN TEST FAILURES PROMPTS GUILTY PLEA
Executive Summary
Warner-Lambert's Fajardo, P.R. plant will be cleared under FDA's application integrity policy in the near future, the company said following its guilty plea in a case stemming from failure to report stability failures of drugs, some of which were manufactured in the plant.
You may also be interested in...
Will Biosimilars Lead To Better Biologics Manufacturing?
US FDA Commissioner Gottlieb is promising new policies to improve biologics manufacturing as part of agency’s action plan to accelerate biosimilar development. That follows the pattern set 25 years ago with generic drugs and brand manufacturing.
Will Biosimilars Lead To Better Biologics Manufacturing?
US FDA Commissioner Gottlieb is promising new policies to improve biologics manufacturing as part of agency’s action plan to accelerate biosimilar development. That follows the pattern set 25 years ago with generic drugs and brand manufacturing.
Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe
Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with FDA